Travere Therapeutics names Jula Inrig EVP, head of R&D, as CRO William Rote plans 2027 retirement

Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

TVTX

0.00
  • Travere Therapeutics chief research officer William Rote plans to retire in February 2027.
  • Chief medical officer Jula Inrig will become executive vice president, head of research and development, retaining the CMO post.
  • Inrig joined Travere in January 2022; she previously served as global head of the Renal Center of Excellence at IQVIA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606161630BIZWIRE_USPR_____20260616_BW896480) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.